p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignanciesEric Wattel, Pierre Fenaux, Claude Preudhomme et al.|Blood|1994Cited by 581
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathwayJizhong Liu, Bruno Quesnel|Blood|2007Cited by 575
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al.|Leukemia|2011Cited by 464
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Hervé Dombret, Emmanuel Raffoux et al.|The Lancet Haematology|2016Cited by 431
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)Nicolas Boissel, Claude Preudhomme, Harmony Leroy et al.|Leukemia|2006Cited by 355